Modality
Nanobody
MOA
USP1i
Target
Nectin-4
Pathway
Neuroinflam
MDDET
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
Jan 2017
→ Dec 2027
Phase 1Current
NCT05864203
1,502 pts·MDD
2020-07→TBD·Active
NCT05421631
2,100 pts·MDD
2017-01→2027-12·Recruiting
3,602 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-12-151.7y awayPh2 Data· MDD
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1/2
Recruit…
P1/2
Active
Catalysts
Ph2 Data
2027-12-15 · 1.7y away
MDD
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05864203 | Phase 1/2 | MDD | Active | 1502 | HAM-D |
| NCT05421631 | Phase 1/2 | MDD | Recruiting | 2100 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| ION-3857 | Ionis | Preclinical | Nectin-4 | |
| Pexanaritide | Innovent Bio | Preclinical | SGLT2 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 |